Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737905 | 1.00 | MAPT (0.44) | MAPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL7829270 | 0.92 | CASP3 (0.46) | MAPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL7829265 | 0.92 | CASP3 (0.46) | MAPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL5735950 | 0.85 | NPC1 (0.39) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5737830 | 0.85 | MAPT (0.39) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8773925 | 0.85 | TAAR1 (0.40) | MAPTCASP3SENP8SENP7SENP6 | |
| SCHEMBL5734335 | 0.82 | MAPT (0.36) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5734338 | 0.82 | MAPT (0.36) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7830027 | 0.81 | MAPT (0.44) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23179843 | 0.80 | TAAR1 (0.43) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390356-B1 | ARYLISOXAZOLINE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF AS PESTICIDES | BAYER CROPSCIENCE GMBH (DE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1390356-A1 | ARYLISOXAZOLINE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF AS PESTICIDES | Bayer CropScience GmbH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6645984-B2 | Mixtures of insecticides, miticides, nematocides, attractants, sterilizers, nematocides, fungicides or molluscides, used for protecting plants and/or seeds, or seals, paints, lubricants for metal working, drilling or cutting oil additives | AVENTIS CROPSCIENCE GMBH (DE) | 2003-11-11 | — | — | US | disclosed |
| US-20030114501-A1 | Arylisoxazoline derivatives, processes for their preparation and their use as pesticides | MERIAL, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002076956-A1 | ARYLISOXAZOLINE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF AS PESTICIDES | BAYER CROPSCIENCE GMBH (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114501-A1 | Arylisoxazoline derivatives, processes for their preparation and their use as pesticides | CBR1, CBR3, CYP4X1 | MAPT 4728/4885CASP3 431/4885SENP8 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.